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The long QT syndrome in South Africa
diagnosis of LQTS in close relatives is often present. Reviews covering 
the background in the text are available(1-3) and references are given 
selectively or if of specifi c South African (SA) relevance. 
GENETICS
Classically, an autosomal dominant inherited form of LQTS, the 
Romano-Ward syndrome (RWS) and an autosomal recessively 
inherited form associated with neuronal deafness, Jervell and Nielsen-
Lange syndrome (JNLS), have been described. Today RWS and JNLS 
are overarching terms for a group of diseases genetically and 
phenotypically quite diverse. At least eight genes with more than 400 
causal-mutations have been associated with LQTS. Defective cardiac 
ion channels or proteins involved in modulating ion currents form a 
common theme and, barring two instances, the LQTSs are associated 
with a pure cardiac phenotype. Andersen-Tawil syndrome (KCNJ2; 
LQT7), fi rstly, is a disease with periodic skeletal muscle paralysis and 
anomalies such as low-set ears, cleft palate and limb defects.  Secondly, 
Timothy syndrome (CACNA1C; LQT8) is associated with short 
stature, syndactyly, baldness at birth and teeth abnormalities.
The three ionic currents most commonly involved in lengthening of the 
cardiac action potential and explaining QT prolongation are IKs, IKr and 
INa. Genes involved are:
1.   IKs current: KCNQ1 (LQT1) and KCNE1 (LQT5), encoding co-
operating protein units for a K+ channel, with defects in either causing 
RWS or JNLS; 
2.   IKr current: KCNH2 (LQT2) and KCNE2 (LQT6), similarly encoding 
co-operating protein units for a K+ channel with defects causing 
RWS;
3.   INa current: SCNA5 (LQT3) encoding a Na
+ channel with defects 
causing RWS.
In JNLS individuals are either homozygous for KCNQ1 mutations or 
compound heterozygotes for KCNQ1 and KCNE1.
BIO-ELECTRIC PHENOMENA
Both in LQT1 (IKs) and LQT2 (IKr) repolarization is retarded in some 
cardiac cell types, ergo a prolonged QT-interval on the surface ECG. 
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The long QT syndromes (LQTS) are 
Mendelian inherited conditions where syncope and sudden 
death are due to precipitous occurrence of polymorphic 
ventricular tachycardia. In South Africa a number of white, 
some coloured and some Asian individuals have been 
identifi ed but, interestingly, not a single black person and 
neither has it been reported from Africa. With over 400 
known causal-mutations, mostly in cardiac ion channel-
genes, it is unlikely to be absent in African populations. 
LQTS is notorious for going undiagnosed or misdiagnosed, 
perhaps even more so in Africa. Amongst persons of 
Afrikaner descent the KCNQ1 A341V-mutation represents 
a founder effect. The availability of 170 living individuals 
sharing the same mutation has made it possible to study 
factors modifying risk. A blunted autonomic response has 
been shown to decrease risk of attacks. SAHeart 2008; 5:160-163
ABSTRACT
LONG QT SYNDROME
The long QT syndrome (LQTS) is recognized by episodes of syncope 
or sudden death and a prolonged QT interval corrected for heart rate, 
the QTc, on an ECG. Other important features on an ECG lie in the 
variable shape of the T wave. Episodes of transient loss of consciousness 
(TLOC) result from polymorphic ventricular tachycardia (torsade de 
pointes) and a family history of sudden unexpected death or the 
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K+ fl ows are either too late or too little. LQT3 (INa), represent a “gain 
of function” with inappropriately large amounts of Na+ fl owing into 
the cell over a prolonged time and thus prolonging the action potential. 
Arrhythmogenic substrate derives from excessive differences created 
in repolarization potential between different cell types in different areas 
of myocardium leading to re-entry potential. 
Interestingly, switching of roles, i.e. gain of function of IKs and IKr, lead 
to the short QT syndrome and loss of function of INa to Brugada 
syndrome, all being other disorders associated with polymorphic 
ventricular tachycardia. 
GENE-ASSOCIATED CLINICAL DISEASES
KCNQ1 (LQT1): Episodes of TLOC are commonly exercise related in 
±70% of cases.(4) Four associated ECG patterns are  an infantile pattern, 
a broad-based T wave, a normal-appearing T wave and a late-onset 
normal-appearing T wave pattern.(5)
KCNH2 (LQT2): Attacks have commonly been correlated with 
emotional events (sudden fright / noise), but with signifi cant pro-
portions also exercise and sleep or rest related.(4) Four common ECG 
patterns all with bifi d T-waves have been described ranging through the 
obvious and the subtle with the second component appearing in 
various places on the T or U wave.(5)
SCNA5 (LQT3): The great majority of attacks occur during rest or 
sleep without arousal.(4) ECG features are late-onset peaked/biphasic 
T waves or an asymmetrical peaked T wave.(5)
MANAGEMENT
One needs to differentiate between acquired, for example, drug 
mediated, and inherited forms of QT prolongation. Information on 
drugs that cause torsade de pointes, prolong the QT interval or are 
specifi cally contraindicated in LQTS are maintained at Arizona CERT 
(http://www.qtdrugs.org). Even “acquired” QT  prolongation could be 
the result of an inherited predisposition uncovered by medication.(6)
Treatment entails avoiding offending drugs and situations associated 
with attacks. The mainstay is ß-blocker treatment and, especially useful 
in LQT1, a partial left-sided sympathectomy.(1) Pacemakers, or commonly 
nowadays an implanted cardioverter-defi brillator (ICD) which has a 
pacing mode, can be used if bradycardia, important either as a primary 
manifestation of the disease or related to ß-blocker use, is problematic. 
In individuals deemed high risk of suffering sudden death an ICD will 
act as a safety net, but the decision to implant should not be taken 
lightly as signifi cant device-associated risk exists.
THE SOUTH AFRICAN EXPERIENCE WITH LQTS
Of 46 index cases (multiple affected from a single family count as one; 
LQTS total 200+) that came to our attention most are white (84.8%), 
some of mixed descent (10.9%) and Asiatic (4.3%) (updated).(7) No 
black persons have been referred to or identifi ed by us and a PUBMED 
search produced no reports from Africa other than our own.(7) In 
contrast, African Americans are not uncommon amongst LQTS 
populations.(3) Remarkably out of 39 white index individuals 23 (59%) 
have the same KCNQ1 A341V mutation in the transmembrane region 
of the protein. This is the result of a founder effect amongst the 
Afrikaners which could be traced to a couple married in approximately 
AD 1730.(8,9) Of the other cases mutations have been detected in 
KCNQ1, KCNH2 and KCNE1 (Durrheim, unpublished results). No 
case of JNLS has come to our attention and screening of children with 
neuronal deafness at schools for the deaf is ongoing (Hofmeyr, 
unpublished results). 
In the fi rst 51 symptomatic cases of the KCNQ1 A341V mutation that 
we identifi ed 40% were misdiagnosed as epilepsy, 31% undiagnosed 
and only 29% diagnosed.(10) In the UK it has been estimated that as 
many as 20% of epilepsy diagnoses are wrong, TLOC being either due 
to arrhythmic events or pseudo TLOC.(11) In Africa a range of possibilities 
for undiagnosed LQTS exist, ranging from lack of meaningful 
communication (time available, language and cultural barriers) and the 
high burden of infectious disease, malnutrition and trauma causing 
premature death(12) and camoufl aging rare diseases.
THE KCNQ1 A341V (A341V) SOUTH AFRICAN 
FOUNDER EFFECT & CLINICAL SCIENCE
By offering the opportunity to observe phenotypic differences 
infl uenced by environmental or genetic factors other than the primary 
mutation, the founder effect permitted investigation of modifying 
infl uences(9) in LQT1 in 22 families (166 living mutation carriers) as 
described below. 
Severity of the A341 mutation
Compared to LQT1 individuals from an international database with 
many different mutations, A341V-carriers were more symptomatic(9,13) 
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and experienced more LQTS related death.(13) By age 40 years 79% of 
A341V-carriers were symptomatic vs. 30% in the international registry.(9) 
This high degree of symptoms is a mutation-specifi c effect and not the 
result of environment or genetic modifi ers in the SA A341V group as 
risk was the same in other ethnic groups.(13) Furthermore, comparing 
A341V to non-A341V LQT1 carriers, A341V-carriers were more likely 
to have had events (75% vs. 24%), were younger at fi rst event (6 vs. 11 
years), and had a longer QTc (485±43 vs. 465±38 ms).  A341V patients 
also had more events even when on ß-blocker therapy.
The explanation for severity may partially reside in that A341V has a 
moderate dominant-negative effect and not a pure loss of function in 
patch clamp experiments.(9) However, this does not tell the whole story 
as arrhythmic risk remained higher when the A341V carriers were 
compared with KCNQ1 mutations with a strong dominant negative 
effect and with mutations within the C- and N-terminals of the 
protein.(13) 
Infl uence of the QTc and the autonomic nervous system on 
disease severity
Lower heart rates (HR) were associated with lower risk of attacks(9,14) 
in persons with QTc <500ms. With a QTc >500ms virtually everybody 
had episodes consistent with this being recognized as a major risk 
predictor.(15) Most asymptomatic individuals were found in the group 
with a QTc <500ms and HR <60bpm. The association with low HR 
led us to propose that other markers of autonomic response could 
be important and we investigated baro-receptor sensitivity (BRS). The 
BRS was lower in asymptomatic than symptomatic A341V carriers. 
A341V carriers with both lower HR and BRS were less frequently 
symptomatic than those with different patterns (20% vs. 76%). Thus 
lower resting HR and “relatively low” BRS are protective factors in 
KCNQ1-A341V carriers, which goes contrary to the experience with 
post myocardial infarction (MI) subjects where lower degrees of BRS 
had been associated with a higher frequency of sudden death.(16) 
A plausible underlying mechanism preventing arrhythmias in LQT1 is 
that a blunted autonomic response averts rapid HR changes when IKs 
is reduced. Thus a physiological risk modifi er with opposing effects in 
different arrhythmogenic substrates has been identifi ed. 
Pregnancy risk
Historic information of 115 pregnancies in 36 women with the A341V 
(LQT1) mutation was obtained with unaffected sisters as controls.(17) 
Likely LQTS related events at any time in life; the nine-month interval 
preceding pregnancy, pregnancy and labour and the nine-month post 
partum interval were compared. LQT1-affected pregnant women 
were at low risk for cardiac events and had no events when ß-blockers 
were used. Higher than expected risk post partum in an earlier 
systematic study in non-genotyped LQTS(18) could possibly be explained 
by the unrecognized presence of LQT2.(19) Furthermore, in our study 
there were no excess risks of miscarriage and no segregation distortion. 
The tendency to bradycardia of LQTS possibly leads to misdiagnosis of 
fetal distress in a number of cases and may also partly explain an excess 
of Cesarean sections in carriers. Beta-blockers had no serious neonatal 
complications and remain recommended during pregnancy.  
In similar vein, general surgery and anesthesia, based on information at 
our disposal but not formally analyzed, seems not to carry excessive 
risk. 
CONCLUSIONS
Studies of LQTS in South Africa are scientifi cally fertile because of the 
presence of a founder effect. Information gained will help to manage 
LQTS-affl icted individuals. The possibility of LQTS should be entertained 
in women and children with an incidentally discovered QTc ≥470ms 
and QTc ≥450ms in men, bizarre repolarization patterns, unexplained 
syncope, and/or a family history of sudden unexpected death. 
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